Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression - PubMed (original) (raw)

Review

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

S N Sehgal. Clin Biochem. 1998 Jul.

Abstract

Rapamune is a novel immunosuppressive agent in Phase III clinical trial in renal transplantation. Its unique mechanism of action has created great interest in its use as a biochemical probe of signal transduction pathways that has provided insight into its molecular mechanism of action. This article reviews the current state of our understanding of the mechanism of action of rapamune.

PubMed Disclaimer

Similar articles

• Mechanism of action of the immunosuppressant rapamycin.
  Dumont FJ, Su Q. Dumont FJ, et al. Life Sci. 1996;58(5):373-95. doi: 10.1016/0024-3205(95)02233-3. Life Sci. 1996. PMID: 8594303 Review.
• Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin.
  Siekierka JJ. Siekierka JJ. Immunol Res. 1994;13(2-3):110-6. doi: 10.1007/BF02918272. Immunol Res. 1994. PMID: 7539823 Review.
• Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.
  Powell JD, Lerner CG, Schwartz RH. Powell JD, et al. J Immunol. 1999 Mar 1;162(5):2775-84. J Immunol. 1999. PMID: 10072524
• Mechanism of action of rapamycin (Sirolimus, Rapamune).
  Molnar-Kimber KL. Molnar-Kimber KL. Transplant Proc. 1996 Apr;28(2):964-9. Transplant Proc. 1996. PMID: 8623482 Review. No abstract available.
• Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
  [No authors listed] [No authors listed] Drugs R D. 1999 Jan;1(1):100-7. doi: 10.2165/00126839-199901010-00033. Drugs R D. 1999. PMID: 10566001 No abstract available.

Cited by

• Safety Evaluation of Oral Sirolimus in the Treatment of Childhood Diseases: A Systematic Review.
  Zhang Z, Li Y, Zhang G, Yang K, Qiu T, Zhou J, Gong X, Ji Y. Zhang Z, et al. Children (Basel). 2022 Aug 26;9(9):1295. doi: 10.3390/children9091295. Children (Basel). 2022. PMID: 36138604 Free PMC article. Review.
• Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats.
  Liu YX, Jin LM, Zhou L, Xie HY, Jiang GP, Chen H, Zheng SS. Liu YX, et al. Dig Dis Sci. 2010 Aug;55(8):2255-62. doi: 10.1007/s10620-009-1002-2. Epub 2009 Oct 24. Dig Dis Sci. 2010. PMID: 19856103
• Role of Sirolimus in renal tubular apoptosis in response to unilateral ureteral obstruction.
  Yang M, Zhuang YY, Wang WW, Zhu HP, Zhang YJ, Zheng SL, Yang YR, Chen BC, Xia P, Zhang Y. Yang M, et al. Int J Med Sci. 2018 Sep 7;15(13):1433-1442. doi: 10.7150/ijms.26954. eCollection 2018. Int J Med Sci. 2018. PMID: 30443162 Free PMC article.
• Case report: Corticosteroid-resistant nephrotic syndrome: treatment with rapamune.
  Jose Miguel L, Vallejo GV. Jose Miguel L, et al. Pediatr Nephrol. 2007 Feb;22(2):315-6. doi: 10.1007/s00467-006-0302-4. Epub 2006 Sep 15. Pediatr Nephrol. 2007. PMID: 16977471 No abstract available.
• The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy.
  Geissler EK. Geissler EK. Transplant Res. 2013 Nov 20;2(Suppl 1):S2. doi: 10.1186/2047-1440-2-S1-S2. Epub 2013 Nov 20. Transplant Res. 2013. PMID: 24565200 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information